Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
112 hedge funds and large institutions have $178M invested in Lumos Pharma, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 42 increasing their positions, 33 reducing their positions, and 38 closing their positions.
209% more call options, than puts
Call options by funds: $24.9M | Put options by funds: $8.06M
27% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 33
19% less funds holding
Funds holding: 139 → 112 (-27)
42% less capital invested
Capital invested by funds: $305M → $178M (-$127M)
68% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 38
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$10.5M |
| 2 |
First Eagle Investment Management
New York
|
+$5.95M |
| 3 |
QI
QS Investors
New York
|
+$2.49M |
| 4 |
HT
HAP Trading
New York
|
+$2.08M |
| 5 |
Millennium Management
New York
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$12M |
| 2 |
State Street
Boston,
Massachusetts
|
-$10.3M |
| 3 |
Axa
Paris,
France
|
-$5.04M |
| 4 |
PC
PointState Capital
New York
|
-$5.01M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.33M |
LUMO Hedge Fund Activity: Q2 2016 in Review
112 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q2 2016, worth a combined $178M — down 42% from $305M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of LUMO and 12 opened new positions — a net loss of 26 holders — while 33 trimmed existing stakes and 42 added.
The largest buyer was OrbiMed, adding an estimated $10.5M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $12M sold.
- 112 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q2 2016, down from 139 in Q1 2016.
- Funds reported $178M of Lumos Pharma, Inc. Common Stock stock for Q2 2016, down 42% quarter-over-quarter.
- 12 funds opened new Lumos Pharma, Inc. Common Stock positions in Q2 2016 and 38 closed out, a net change of -26 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q2 2016 was OrbiMed, an estimated $10.5M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q2 2016 was Acadian Asset Management, an estimated $12M sold.
Based on aggregated 13F filings for Q2 2016.